LeukemiaPhase 3NCT00003437
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
A Phase 3 study testing asparaginase, cyclophosphamide and cytarabine in people with Leukemia, run by Medical Research Council at 1 site in United Kingdom.
Trial summary
RATIONALE: Hormone therapy may stop the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more cancer cells. Read more about this study
- Who is it for?
- Ages 1 year to 18 years
- Conditions the study is for
- Leukemia
- What is being tested?
- asparaginase, cyclophosphamide and cytarabine
- Type of treatment
- Surgery or procedure
- How many people
- 1,800 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 1997to not given
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
DISEASE CHARACTERISTICS:
- Histologically confirmed acute lymphoblastic leukemia (ALL)
- No B-ALL (Burkitt-like, t(8;14), L3 morphology, SMIg positive)
- Meets criteria for one of the following risk groups:
- Standard risk
- 1 to 9 years old
- Highest WBC less than 50,000/mm^3
- BCR-ABL negative
- Not hypodiploid
- No MLL gene rearrangements if 12 to 24 months old
- Intermediate risk
- Over 10 years old AND/OR
- WBC greater than 50,000/mm^3
- BCR-ABL negative
- Not hypodiploid
- No MLL gene rearrangement if 12 to 24 months old
- High risk, defined by at least 1 of the following:
- Slow early response with regimen A or B
- BCR-ABL positive
- Hypodiploid
- MLL gene rearrangement and 12 to 24 months old
PATIENT CHARACTERISTICS:
Age:
- 1 to 18
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- See Disease Characteristics
Hepatic:
- Not specified
Renal:
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- Previous treatment with HR1 regimens allowed
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Oxford Radcliffe Hospital
Oxford, England, 0X3 9DU
About this study
Official title: Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial
RATIONALE: Hormone therapy may stop the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more cancer cells. It is not yet known which hormone therapy and chemotherapy regimen is most effective for acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of different steroid therapy and chemotherapy regimens in treating children who have acute lymphoblastic leukemia.
Read the detailed description
OBJECTIVES:
- Compare the effects of oral prednisolone vs oral dexamethasone on remission rate, event-free survival, and overall survival of children with acute lymphoblastic leukemia.
- Compare the effect of oral mercaptopurine (MP) vs oral thioguanine (TG) on remission rate, event-free survival, and overall survival of this patient population.
- Assess the effect of a schedule concentrating on tight control of maintenance therapy, compensating where necessary for constitutional drug resistance and avoiding poor physician or patient compliance, on event-free survival of these patients.
- Compare the pharmacokinetics of MP and TG in these patients.
- Collect data on the presence or absence of minimal residual disease in serial bone marrow samples to assess its clinical importance.
OUTLINE: This is a randomized, multicenter study. Patients are randomized twice during the study: prednisolone vs dexamethasone and mercaptopurine vs thioguanine. Patients are initially stratified according to risk status (standard vs intermediate vs high). Patients are stratified at the second randomization according to gender, age (under 2 years vs 2 to 9 years vs over 9 years), WBC (under 50,000/mm^3 vs over 50,000/mm^3), steroid allocation, and early response (slow vs rapid).
Patients with verified CNS disease receive weekly intrathecal (IT) methotrexate until 2 consecutive clear cerebrospinal fluid samples have been obtained. Cranial radiotherapy is administered over 15-21 days during weeks 5-8 concurrently with methotrexate IT in the appropriate regimen. Following radiotherapy, these patients receive monthly methotrexate IT for 1 year and then every 3 months until the end of therapy.
Patients with testicular infiltration receive additional radiation fractions daily for 12 days to both testes during weeks 5-8.
Regimen A (standard-risk patients)
- Remission induction: Patients receive the assigned oral steroid (prednisolone or dexamethasone) twice a day on days 1-28; vincristine IV on days 1, 8, 15, and 22; and asparaginase IM three days a week for 9 doses beginning on day 4. Patients also receive cytarabine IT on day 1 and methotrexate IT on day 8.
- If bone marrow is M3 at day 15 or M2 at day 29, therapy continues on regimen C. Otherwise, patient continues on regimen A.
- Consolidation: Patients taper the assigned steroid over days 29-35, plus receive vincristine IV on day 29 and methotrexate IT on days 29, 36, 43, and 50. Patients also receive oral thiopurine (mercaptopurine or thioguanine) on days 29-56.
- Interim maintenance I: Patients receive the assigned oral steroid twice a day on days 57-61 and 85-89 plus vincristine IV on days 57 and 85. Patients also receive the assigned oral thiopurine on days 57-105 and oral methotrexate on days 57, 64, 71, 78, 85, 92, 99, and 106.
- Delayed intensification I: Patients receive oral dexamethasone twice a day on days 113-119 and 127-133, plus vincristine IV and daunorubicin IV over 6 hours on days 113, 120, and 127. Patients also receive asparaginase IM three days a week for 6 doses beginning on day 114 or 115 and methotrexate IT on day 113. Cyclophosphamide IV over 30 minutes is administered on day 141. Patients also receive oral thioguanine on days 141-154, cytarabine IV or subcutaneously (SC) twice a day on days 142-145 and 149-152, and methotrexate IT on days 141 and 148.
- Interim maintenance II: Patients receive the assigned oral steroid twice a day on days 162-166 and 190-194 and vincristine IV on days 162 and 190. Patients also receive the assigned oral thiopurine on days 162-210 and oral methotrexate on days 162, 169, 176, 183, 190, 197, 204, and 211.
- Delayed intensification II: Patients receive oral dexamethasone on days 218-224 and 239-245; vincristine IV and doxorubicin IV over 6 hours on days 218, 225, and 232; and methotrexate IT on day 218. Asparaginase IM is administered three days a week for 6 doses beginning on day 219 or 220. Patients then receive cyclophosphamide IV over 30 minutes on day 246, oral thioguanine on days 246-259, cytarabine IV or SC on days 247-250 and 254-257, and methotrexate IT on days 246 and 253.
- Maintenance: Treatment is given as a 12-week course for 6 courses (girls) or 11 courses (boys). Patients receive the assigned oral steroid twice a day on days 1-5, 29-33, and 57-61 of each course, vincristine IV on days 1, 29, and 57 of each course, and the assigned oral thiopurine daily during each course. Methotrexate IT is administered to girls on day 1 of each course and on day 84 of course 6, while boys receive 1 dose on day 1 of course 11. Patients also receive oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each course.
Regimen B (intermediate-risk patients)
- Remission induction: Patients receive the assigned oral steroid, vincristine, and asparaginase as in regimen A remission induction. Patients also receive daunorubicin IV over 6 hours on days 1, 8, 15, and 22; cytarabine IT on day 1; and methotrexate IT on day 8.
- If bone marrow is M3 at day 8 or M2 at day 29, therapy continues on regimen C. Otherwise, patient continues on regimen B.
- Consolidation: The assigned steroid is tapered over days 29-35. Patients also receive cyclophosphamide IV over 30 minutes on days 29 and 43; cytarabine IV or SC on days 30-33, 37-40, 44-47, and 51-54; oral mercaptopurine on days 29-56; and methotrexate IT on days 29, 36, 43, and 50.
- Patients with M1 or M2 bone marrow on day 64 proceed to interim maintenance I.
- Interim maintenance I: Patients receive the assigned steroid, vincristine, the assigned thiopurine, and oral methotrexate as in regimen A. Patients also receive methotrexate IT on days 64 and 92.
- Delayed intensification I: Patients receive oral dexamethasone on days 120-126 and 134-140, plus vincristine IV and doxorubicin IV over 6 hours on days 120, 127, and 134. Patients also receive asparaginase IM three days a week for 6 doses beginning on day 121 or 122 and methotrexate IT on day 120. Patients then receive cyclophosphamide IV over 30 minutes on day 148, oral thioguanine on days 148-161, cytarabine IV or SC on days 149-152 and 156-159, and methotrexate IT on days 148 and 155.
- Interim maintenance II: Patients receive the assigned oral steroid twice a day on days 169-173 and 197-201; vincristine IV on days 169 and 197; the assigned oral thiopurine on days 169-217; oral methotrexate on days 176, 183, 190, 197, 204, and 211; and methotrexate IT on days 169 and 197.
- Delayed intensification II: Patients receive oral dexamethasone on days 225-231 and 239-245; vincristine IV and doxorubicin IV over 6 hours on days 225, 232, and 239; and methotrexate IT on day 225. Asparaginase IM is administered three days a week for 6 doses beginning on day 226 or 227. Patients then receive cyclophosphamide IV over 30 minutes on day 253, oral thioguanine on days 253-266, cytarabine IV or SC on days 253-256 and 260-263, and methotrexate IT on days 253 and 260.
- Maintenance: Treatment is administered as in regimen A.
Regimen C (Slow early response to regimen A or B OR high-risk patients)
- Remission induction for patients switching from regimen A: Patients continue assigned oral steroid for a total of 35 days. Patients also receive vincristine IV on days 15, 22, and 29, and daunorubicin IV over 6 hours on days 15 and 22. Asparaginase IM is administered 3 days a week for 6 doses. Patients receive methotrexate IT on day 29 (patients with CNS disease also receive doses on days 15 and 22).
- Remission induction for patients switching from regimen B: Patients continue assigned oral steroid for a total of 35 days. Patients also receive vincristine IV and daunorubicin IV over 6 hours on days 8, 15, and 22. Asparaginase IM continues three days a week for up to 6 doses. Patients also receive methotrexate IT on day 29 (patients with CNS disease also receive doses on days 14 and 21).
- Consolidation: Patients receive cyclophosphamide IV over 30 minutes on days 36 and 64; cytarabine IV or SC on days 37-40, 44-47, 65-68, and 72-75; oral mercaptopurine on days 36-49 and 64-77; vincristine IV on days 50, 57, 78, and 85; pegaspargase IM on days 50 and 78; and methotrexate IT on days 36, 43, 50, and 57.
- Interim maintenance I: Patients receive vincristine IV and methotrexate IV on days 99, 109, 119, 129, and 139. Pegaspargase IM is administered on days 100 and 110 and methotrexate IT is administered on days 99 and 129 (patients with CNS disease do not receive the dose on day 129).
- Patients with M1 or M2 bone marrow proceed to delayed intensification I.
- Delayed intensification I:
- Reinduction: Patients receive vincristine IV and doxorubicin IV over 6 hours on days 162, 169, and 176; oral dexamethasone twice a day on days 162-168 and 176-82; methotrexate IT on day 162; and pegaspargase IM on day 165.
- Reconsolidation: Patients receive cyclophosphamide IV over 30 minutes on day 190, oral thioguanine on days 190-203, cytarabine IV or SC on days 191-194 and 197-200, vincristine IV on days 204 and 211, and pegaspargase IM on day 204. Methotrexate IT is administered on days 190 and 197 (patients with CNS disease do not receive the dose on day 197).
- Interim maintenance II: Patients receive vincristine IV and methotrexate IV on days 218, 228, 238, 248, and 258. Pegaspargase IM is administered on days 219 and 239. Patients also receive methotrexate IT on days 218 and 248 (patients with CNS disease do not receive the dose on day 248).
- Delayed intensification II:
- Reinduction: Patients receive vincristine IV and doxorubicin IV over 6 hours on days 274, 281, and 288; oral dexamethasone twice a day on days 274-280 and 288-294; methotrexate IT on day 274; and pegaspargase IM on day 277.
- Reconsolidation: Patients receive cyclophosphamide IV over 30 minutes on day 302, oral thioguanine on days 302-315, cytarabine IV or SC on days 303-306 and 309-312, and vincristine IV on days 316 and 323.
- Maintenance: Treatment is administered as in regimen A.
PROJECTED ACCRUAL: Approximately 1,800 patients will be accrued for this study within 6 years.
- Conditions
- Leukemia
- Being tested
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone
- Keywords
- recurrent childhood acute lymphoblastic leukemia, untreated childhood acute lymphoblastic leukemia
- Medical subject headings
- Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
asparaginaseDrug
cyclophosphamideDrug
cytarabineDrug
daunorubicin hydrochlorideDrug
dexamethasoneDrug
mercaptopurineDrug
methotrexateDrug
pegaspargaseDrug
prednisoloneDrug
thioguanineDrug
radiation therapyRadiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startJan 1997
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Enrolment
- 1,800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical Research Council
- Sponsor type
- Other government
- Investigators
- C. Mitchell, Study chair, Oxford University Hospitals NHS Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00003437
- Sponsor's protocol ID
- CDR0000066464
- Other IDs
- MRC-LEUK-ALL97, EU-97032
- Status last verified
- Feb 2003
- First submitted
- 1 Nov 1999
- Last updated
- 4 Dec 2013
- Results posted
- No
Publications
Krishnan S, Wade R, Moorman AV, Mitchell C, Kinsey SE, Eden TO, Parker C, Vora A, Richards S, Saha V. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia. 2010 Feb;24(2):450-9. doi: 10.1038/leu.2009.264. Epub 2009 Dec 17.
PubMed 20016529Mitchell C, Payne J, Wade R, Vora A, Kinsey S, Richards S, Eden T. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol. 2009 Aug;146(4):424-36. doi: 10.1111/j.1365-2141.2009.07769.x. Epub 2009 Jun 22.
PubMed 19549269Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A, Rowe J, Webb D. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007 Mar;48(3):254-61. doi: 10.1002/pbc.20749.
PubMed 16421910Vora A, Ward R, Payne J, et al.: Benefit of targeted intensification for NCI high risk childhood lymphoblastic leukaemia: results of the United Kingdom Medical Research Council trial ALL97 and ALL97/99. [Abstract] Blood 108 (11): A-1869, 2006.
Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T, Easlea D, Meyer LC, Pinkerton CR. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002 Feb;38(2):98-103. doi: 10.1002/mpo.1279.
PubMed 11813173Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011 Feb 17;117(7):2129-36. doi: 10.1182/blood-2010-07-297135. Epub 2010 Nov 24.
PubMed 21106984Moorman AV, Ensor HM, Chilton L, et al.: Prognostic relevance of cytogenetics in childhood acute lymphoblastic leukaemia (ALL): final results from MRC ALL97. [Abstract] Blood 114 (22): A-88, 2009.
Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005 Jun;129(6):734-45. doi: 10.1111/j.1365-2141.2005.05509.x.
PubMed 15952999Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V; Medical Research Council Childhood Leukaemia Working Party. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol. 2005 Apr;129(1):35-44. doi: 10.1111/j.1365-2141.2005.05425.x.
PubMed 15801953Somervaille TC, Hann IM, Harrison G, Eden TO, Gibson BE, Hill FG, Mitchell C, Kinsey SE, Vora AJ, Lilleyman JS; MRC Childhood Leukaemia Working Party. Intraocular relapse of childhood acute lymphoblastic leukaemia. Br J Haematol. 2003 Apr;121(2):280-8. doi: 10.1046/j.1365-2141.2003.04280.x.
PubMed 12694250Wallace AM, Tucker P, Williams DM, Hughes IA, Ahmed SF. Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia. Clin Endocrinol (Oxf). 2003 Jun;58(6):770-6. doi: 10.1046/j.1365-2265.2003.01790.x.
PubMed 12780755Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf). 2002 Aug;57(2):185-91. doi: 10.1046/j.1365-2265.2002.01580.x.
PubMed 12153596Lancaster DL, Patel N, Lennard L, Lilleyman JS. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2002 Jul;50(1):33-6. doi: 10.1007/s00280-002-0442-6. Epub 2002 Apr 27.
PubMed 12111109
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial
- ClinicalTrials.gov ID
- NCT00003437
- Acronym / sponsor ID
- CDR0000066464
- Conditions
- Leukemia
- Keywords
- recurrent childhood acute lymphoblastic leukemia, untreated childhood acute lymphoblastic leukemia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,800 participants (estimated)
- Lead sponsor
- Medical Research CouncilOther government
- Study start
- Jan 1997
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Hormone therapy may stop the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more cancer cells. It is not yet known which hormone therapy and chemotherapy regimen is most effective for acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of different steroid therapy and chemotherapy regimens in treating children who have acute lymphoblastic leukemia.
Detailed description
OBJECTIVES:
- Compare the effects of oral prednisolone vs oral dexamethasone on remission rate, event-free survival, and overall survival of children with acute lymphoblastic leukemia.
- Compare the effect of oral mercaptopurine (MP) vs oral thioguanine (TG) on remission rate, event-free survival, and overall survival of this patient population.
- Assess the effect of a schedule concentrating on tight control of maintenance therapy, compensating where necessary for constitutional drug resistance and avoiding poor physician or patient compliance, on event-free survival of these patients.
- Compare the pharmacokinetics of MP and TG in these patients.
- Collect data on the presence or absence of minimal residual disease in serial bone marrow samples to assess its clinical importance.
OUTLINE: This is a randomized, multicenter study. Patients are randomized twice during the study: prednisolone vs dexamethasone and mercaptopurine vs thioguanine. Patients are initially stratified according to risk status (standard vs intermediate vs high). Patients are stratified at the second randomization according to gender, age (under 2 years vs 2 to 9 years vs over 9 years), WBC (under 50,000/mm^3 vs over 50,000/mm^3), steroid allocation, and early response (slow vs rapid).
Patients with verified CNS disease receive weekly intrathecal (IT) methotrexate until 2 consecutive clear cerebrospinal fluid samples have been obtained. Cranial radiotherapy is administered over 15-21 days during weeks 5-8 concurrently with methotrexate IT in the appropriate regimen. Following radiotherapy, these patients receive monthly methotrexate IT for 1 year and then every 3 months until the end of therapy.
Patients with testicular infiltration receive additional radiation fractions daily for 12 days to both testes during weeks 5-8.
Regimen A (standard-risk patients)
- Remission induction: Patients receive the assigned oral steroid (prednisolone or dexamethasone) twice a day on days 1-28; vincristine IV on days 1, 8, 15, and 22; and asparaginase IM three days a week for 9 doses beginning on day 4. Patients also receive cytarabine IT on day 1 and methotrexate IT on day 8.
- If bone marrow is M3 at day 15 or M2 at day 29, therapy continues on regimen C. Otherwise, patient continues on regimen A.
- Consolidation: Patients taper the assigned steroid over days 29-35, plus receive vincristine IV on day 29 and methotrexate IT on days 29, 36, 43, and 50. Patients also receive oral thiopurine (mercaptopurine or thioguanine) on days 29-56.
- Interim maintenance I: Patients receive the assigned oral steroid twice a day on days 57-61 and 85-89 plus vincristine IV on days 57 and 85. Patients also receive the assigned oral thiopurine on days 57-105 and oral methotrexate on days 57, 64, 71, 78, 85, 92, 99, and 106.
- Delayed intensification I: Patients receive oral dexamethasone twice a day on days 113-119 and 127-133, plus vincristine IV and daunorubicin IV over 6 hours on days 113, 120, and 127. Patients also receive asparaginase IM three days a week for 6 doses beginning on day 114 or 115 and methotrexate IT on day 113. Cyclophosphamide IV over 30 minutes is administered on day 141. Patients also receive oral thioguanine on days 141-154, cytarabine IV or subcutaneously (SC) twice a day on days 142-145 and 149-152, and methotrexate IT on days 141 and 148.
- Interim maintenance II: Patients receive the assigned oral steroid twice a day on days 162-166 and 190-194 and vincristine IV on days 162 and 190. Patients also receive the assigned oral thiopurine on days 162-210 and oral methotrexate on days 162, 169, 176, 183, 190, 197, 204, and 211.
- Delayed intensification II: Patients receive oral dexamethasone on days 218-224 and 239-245; vincristine IV and doxorubicin IV over 6 hours on days 218, 225, and 232; and methotrexate IT on day 218. Asparaginase IM is administered three days a week for 6 doses beginning on day 219 or 220. Patients then receive cyclophosphamide IV over 30 minutes on day 246, oral thioguanine on days 246-259, cytarabine IV or SC on days 247-250 and 254-257, and methotrexate IT on days 246 and 253.
- Maintenance: Treatment is given as a 12-week course for 6 courses (girls) or 11 courses (boys). Patients receive the assigned oral steroid twice a day on days 1-5, 29-33, and 57-61 of each course, vincristine IV on days 1, 29, and 57 of each course, and the assigned oral thiopurine daily during each course. Methotrexate IT is administered to girls on day 1 of each course and on day 84 of course 6, while boys receive 1 dose on day 1 of course 11. Patients also receive oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each course.
Regimen B (intermediate-risk patients)
- Remission induction: Patients receive the assigned oral steroid, vincristine, and asparaginase as in regimen A remission induction. Patients also receive daunorubicin IV over 6 hours on days 1, 8, 15, and 22; cytarabine IT on day 1; and methotrexate IT on day 8.
- If bone marrow is M3 at day 8 or M2 at day 29, therapy continues on regimen C. Otherwise, patient continues on regimen B.
- Consolidation: The assigned steroid is tapered over days 29-35. Patients also receive cyclophosphamide IV over 30 minutes on days 29 and 43; cytarabine IV or SC on days 30-33, 37-40, 44-47, and 51-54; oral mercaptopurine on days 29-56; and methotrexate IT on days 29, 36, 43, and 50.
- Patients with M1 or M2 bone marrow on day 64 proceed to interim maintenance I.
- Interim maintenance I: Patients receive the assigned steroid, vincristine, the assigned thiopurine, and oral methotrexate as in regimen A. Patients also receive methotrexate IT on days 64 and 92.
- Delayed intensification I: Patients receive oral dexamethasone on days 120-126 and 134-140, plus vincristine IV and doxorubicin IV over 6 hours on days 120, 127, and 134. Patients also receive asparaginase IM three days a week for 6 doses beginning on day 121 or 122 and methotrexate IT on day 120. Patients then receive cyclophosphamide IV over 30 minutes on day 148, oral thioguanine on days 148-161, cytarabine IV or SC on days 149-152 and 156-159, and methotrexate IT on days 148 and 155.
- Interim maintenance II: Patients receive the assigned oral steroid twice a day on days 169-173 and 197-201; vincristine IV on days 169 and 197; the assigned oral thiopurine on days 169-217; oral methotrexate on days 176, 183, 190, 197, 204, and 211; and methotrexate IT on days 169 and 197.
- Delayed intensification II: Patients receive oral dexamethasone on days 225-231 and 239-245; vincristine IV and doxorubicin IV over 6 hours on days 225, 232, and 239; and methotrexate IT on day 225. Asparaginase IM is administered three days a week for 6 doses beginning on day 226 or 227. Patients then receive cyclophosphamide IV over 30 minutes on day 253, oral thioguanine on days 253-266, cytarabine IV or SC on days 253-256 and 260-263, and methotrexate IT on days 253 and 260.
- Maintenance: Treatment is administered as in regimen A.
Regimen C (Slow early response to regimen A or B OR high-risk patients)
- Remission induction for patients switching from regimen A: Patients continue assigned oral steroid for a total of 35 days. Patients also receive vincristine IV on days 15, 22, and 29, and daunorubicin IV over 6 hours on days 15 and 22. Asparaginase IM is administered 3 days a week for 6 doses. Patients receive methotrexate IT on day 29 (patients with CNS disease also receive doses on days 15 and 22).
- Remission induction for patients switching from regimen B: Patients continue assigned oral steroid for a total of 35 days. Patients also receive vincristine IV and daunorubicin IV over 6 hours on days 8, 15, and 22. Asparaginase IM continues three days a week for up to 6 doses. Patients also receive methotrexate IT on day 29 (patients with CNS disease also receive doses on days 14 and 21).
- Consolidation: Patients receive cyclophosphamide IV over 30 minutes on days 36 and 64; cytarabine IV or SC on days 37-40, 44-47, 65-68, and 72-75; oral mercaptopurine on days 36-49 and 64-77; vincristine IV on days 50, 57, 78, and 85; pegaspargase IM on days 50 and 78; and methotrexate IT on days 36, 43, 50, and 57.
- Interim maintenance I: Patients receive vincristine IV and methotrexate IV on days 99, 109, 119, 129, and 139. Pegaspargase IM is administered on days 100 and 110 and methotrexate IT is administered on days 99 and 129 (patients with CNS disease do not receive the dose on day 129).
- Patients with M1 or M2 bone marrow proceed to delayed intensification I.
- Delayed intensification I:
- Reinduction: Patients receive vincristine IV and doxorubicin IV over 6 hours on days 162, 169, and 176; oral dexamethasone twice a day on days 162-168 and 176-82; methotrexate IT on day 162; and pegaspargase IM on day 165.
- Reconsolidation: Patients receive cyclophosphamide IV over 30 minutes on day 190, oral thioguanine on days 190-203, cytarabine IV or SC on days 191-194 and 197-200, vincristine IV on days 204 and 211, and pegaspargase IM on day 204. Methotrexate IT is administered on days 190 and 197 (patients with CNS disease do not receive the dose on day 197).
- Interim maintenance II: Patients receive vincristine IV and methotrexate IV on days 218, 228, 238, 248, and 258. Pegaspargase IM is administered on days 219 and 239. Patients also receive methotrexate IT on days 218 and 248 (patients with CNS disease do not receive the dose on day 248).
- Delayed intensification II:
- Reinduction: Patients receive vincristine IV and doxorubicin IV over 6 hours on days 274, 281, and 288; oral dexamethasone twice a day on days 274-280 and 288-294; methotrexate IT on day 274; and pegaspargase IM on day 277.
- Reconsolidation: Patients receive cyclophosphamide IV over 30 minutes on day 302, oral thioguanine on days 302-315, cytarabine IV or SC on days 303-306 and 309-312, and vincristine IV on days 316 and 323.
- Maintenance: Treatment is administered as in regimen A.
PROJECTED ACCRUAL: Approximately 1,800 patients will be accrued for this study within 6 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
Who may qualify
- Ages
- 1 year to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| asparaginase | Drug | – |
| cyclophosphamide | Drug | – |
| cytarabine | Drug | – |
| daunorubicin hydrochloride | Drug | – |
| dexamethasone | Drug | – |
| doxorubicin hydrochloride | Drug | – |
| mercaptopurine | Drug | – |
| methotrexate | Drug | – |
| pegaspargase | Drug | – |
| prednisolone | Drug | – |
| thioguanine | Drug | – |
| vincristine sulfate | Drug | – |
| radiation therapy | Radiation | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2013.
- Background: PubMed 20016529Krishnan S, Wade R, Moorman AV, Mitchell C, Kinsey SE, Eden TO, Parker C, Vora A, Richards S, Saha V. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia. 2010 Feb;24(2):450-9. doi: 10.1038/leu.2009.264. Epub 2009 Dec 17.
- Background: PubMed 19549269Mitchell C, Payne J, Wade R, Vora A, Kinsey S, Richards S, Eden T. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol. 2009 Aug;146(4):424-36. doi: 10.1111/j.1365-2141.2009.07769.x. Epub 2009 Jun 22.
- Background: PubMed 16421910Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A, Rowe J, Webb D. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007 Mar;48(3):254-61. doi: 10.1002/pbc.20749.
- BackgroundVora A, Ward R, Payne J, et al.: Benefit of targeted intensification for NCI high risk childhood lymphoblastic leukaemia: results of the United Kingdom Medical Research Council trial ALL97 and ALL97/99. [Abstract] Blood 108 (11): A-1869, 2006.
- Background: PubMed 11813173Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T, Easlea D, Meyer LC, Pinkerton CR. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002 Feb;38(2):98-103. doi: 10.1002/mpo.1279.
- Results publication: PubMed 21106984Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011 Feb 17;117(7):2129-36. doi: 10.1182/blood-2010-07-297135. Epub 2010 Nov 24.
- Results publicationMoorman AV, Ensor HM, Chilton L, et al.: Prognostic relevance of cytogenetics in childhood acute lymphoblastic leukaemia (ALL): final results from MRC ALL97. [Abstract] Blood 114 (22): A-88, 2009.
- Results publication: PubMed 15952999Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005 Jun;129(6):734-45. doi: 10.1111/j.1365-2141.2005.05509.x.
- Results publication: PubMed 15801953Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V; Medical Research Council Childhood Leukaemia Working Party. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol. 2005 Apr;129(1):35-44. doi: 10.1111/j.1365-2141.2005.05425.x.
- Results publication: PubMed 12694250Somervaille TC, Hann IM, Harrison G, Eden TO, Gibson BE, Hill FG, Mitchell C, Kinsey SE, Vora AJ, Lilleyman JS; MRC Childhood Leukaemia Working Party. Intraocular relapse of childhood acute lymphoblastic leukaemia. Br J Haematol. 2003 Apr;121(2):280-8. doi: 10.1046/j.1365-2141.2003.04280.x.
- Results publication: PubMed 12780755Wallace AM, Tucker P, Williams DM, Hughes IA, Ahmed SF. Short-term effects of prednisolone and dexamethasone on circulating concentrations of leptin and sex hormone-binding globulin in children being treated for acute lymphoblastic leukaemia. Clin Endocrinol (Oxf). 2003 Jun;58(6):770-6. doi: 10.1046/j.1365-2265.2003.01790.x.
- Results publication: PubMed 12153596Ahmed SF, Tucker P, Mushtaq T, Wallace AM, Williams DM, Hughes IA. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clin Endocrinol (Oxf). 2002 Aug;57(2):185-91. doi: 10.1046/j.1365-2265.2002.01580.x.
Related trials for Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
C. Mitchell study chair
Oxford University Hospitals NHS Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing asparaginase, cyclophosphamide and cytarabine in people with Leukemia, run by Medical Research Council at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00003437, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2013.